Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simultaneous vs Sequential mRNA COVID-19 and Influenza Vaccines
NCT05028361Phase 4Completed
- Sponsor
- Duke University
- Start
- Oct 2021
- Primary completion
- Mar 2023
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of mRNA COVID-19 vaccine and influenza virus quadrivalent inactivated vaccine in coronavirus disease 2019 (COVID-19) and influenza (2 arms), sponsored by Duke University. Primary endpoint: Total Number of Participants With Moderate or More Severe Fever, Chills, Myalgia, or Arthralgia in the Simultaneous Group and the Sequential Group Following Both Vaccination Visit 1 and 2. Started Oct 2021; status: completed.
02
Drugs
mRNA COVID-19 vaccineinfluenza virus quadrivalent inactivated vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT05028361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028361.